1873 — VIVA Biotech Holdings Balance Sheet
0.000.00%
- HK$4.16bn
- HK$4.45bn
- CNY1.73bn
Annual balance sheet for VIVA Biotech Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 801 | 679 | 1,036 | 942 | 1,089 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 532 | 505 | 544 | 482 | 386 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,984 | 1,939 | 2,031 | 1,877 | 2,128 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,724 | 1,937 | 1,655 | 1,597 | 1,535 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 8,045 | 7,921 | 7,450 | 7,051 | 7,199 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 927 | 2,673 | 1,534 | 1,127 | 1,411 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4,131 | 4,316 | 3,762 | 3,248 | 3,203 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 3,913 | 3,605 | 3,688 | 3,802 | 3,997 |
| Total Liabilities & Shareholders' Equity | 8,045 | 7,921 | 7,450 | 7,051 | 7,199 |
| Total Common Shares Outstanding |